Asuragen's test detects cystic fibrosis gene variants

By The Science Advisory Board staff writers

November 8, 2021 -- Asuragen, a Bio-Techne brand, has launched a new test kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The AmplideX PCR/CE CFTR Kit, which is intended for research use only, delivers results in less than five hours. It is designed to detect approximately 93% of CFTR pathogenic variants observed in the U.S. population. It can also identify a broad range of variant types, including copy number variants; single tandem repeats; and single nucleotide polymorphisms, insertions, and deletions. The kit can resolve variant zygosity.

Furthermore, it is optimized for use on polymerase chain reaction (PCR) and capillary electrophoresis laboratory equipment, and the kit can be combined with Asuragen's AmplideX PCR/CE FMR1 Kit and the SMN1/2 Plus Kit to provide the same-platform assay for this trio of the most prevalent and commonly analyzed carrier genes.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.